Stock ALPN ALPINE IMMUNE SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Alpine Immune Sciences, Inc.

Equities

ALPN

US02083G1004

Delayed Nasdaq
Other stock markets
 16:00:00 2024-05-17 EDT 		5-day change 1st Jan Change
64.97 USD +0.02% Intraday chart for Alpine Immune Sciences, Inc. -.--% +240.87%
05-20 Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from NASDAQ Composite Index CI
05-20 Vertex Pharmaceuticals Incorporated completed the acquisition of Alpine Immune Sciences, Inc. from a group of shareholders. CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
TD Cowen Downgrades Alpine Immune Sciences to Hold From Buy
MT
Leerink Partners Downgrades Alpine Immune Sciences to Market Perform From Outperform
MT
Wolfe Research Downgrades Alpine Immune Sciences to Peer Perform From Outperform
MT
HC Wainwright Downgrades Alpine Immune Sciences to Neutral From Buy, Raises Price Target to $65 From $50
MT
Guggenheim Downgrades Alpine Immune Sciences to Neutral From Buy, Raises Price Target to $65 From $55
MT
Wedbush Downgrades Alpine Immune Sciences to Neutral From Outperform, Raises Price Target to $65 From $47, Expects Vertex Deal to Close
MT
Morgan Stanley Downgrades Alpine Immune Sciences to Equalweight From Overweight, Raises Price Target to $65 From $47
MT
RBC Downgrades Alpine Immune Sciences to Sector Perform From Outperform, Removes Speculative Risk, Lifts Price Target to $65 From $41 Amid Vertex Deal
MT
Morgan Stanley Adjusts Price Target on Alpine Immune Sciences to $47 From $30, Maintains Overweight Rating
MT
Oppenheimer Raises Alpine Immune Sciences Price Target to $44 From $33, Maintains Outperform Rating
MT
HC Wainwright Adjusts Alpine Immune Sciences Price Target to $50 From $32, Maintains Buy Rating
MT
Wedbush Adjusts Alpine Immune Sciences' PT to $47 From $35, Maintains Outperform Rating
MT
RBC Raises Price Target on Alpine Immune Sciences to $41 From $29, Keeps Outperform, Speculative Risk
MT
Wolfe Research Initiates Alpine Immune Sciences With Outperform Rating, $44 Price Target
MT
Oppenheimer Raises Alpine Immune Sciences Price Target to $33 From $30, Maintains Outperform Rating
MT
Wedbush Raises Alpine Immune Sciences' PT to $35 From $26 After Updated Data From Study Evaluating Atacicep in IgA Nephropathy; Maintains Outperform Rating
MT
RBC Raises Price Target on Alpine Immune Sciences to $29 From $22, Cites 'Attractive Setup,' Keeps Outperform, Speculative Risk
MT
HC Wainwright Adjusts Price Target on Alpine Immune Sciences to $32 From $17, Keeps Buy Rating
MT
Morgan Stanley Adjusts Price Target on Alpine Immune Sciences to $30 From $17, Maintains Overweight Rating
MT
RBC Boosts Price Target on Alpine Immune Sciences to $22 From $19, Keeps Outperform, Speculative Risk
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALPN Stock
  4. News Alpine Immune Sciences, Inc.
  5. Analyst Reco.